News Column

Report Summarizes Cancer Therapy Study Findings from Peking University

June 18, 2014

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Oncology. According to news reporting originating in Beijing, People's Republic of China, by NewsRx journalists, research stated, "Amoitone B, a natural agonist to Nur77, is a promising anticancer drug. However, its application is seriously restricted due to the water-insolubility and short biological half-life."

The news reporters obtained a quote from the research from Peking University, "Amoitone B nanocrystals (AmB-NC) were formulated by microfluidization method to overcome the above obstacles. This study aims to evaluate the cytotoxicity and tissue distribution of AmB-NC. MIT [3-(4,5-dimethylthiazol-2-y1)2,5-diphenyltetrazolium bromide] assay revealed the improved in vitro antitumor activity of AmB-NC against stomach, colon, liver and lung cancer cells compared with Amoitone B solution. Meanwhile, observation of morphological changes, cell cycle and apoptosis examination using flow cytometry exhibited that AmB-NC could induce G1 cycle arrest and markedly enhance the apoptosis of human gastric cancer BGC-823 cell line. Tissue distribution study demonstrated that AmB-NC had a higher distribution in liver and lung, which was helpful for relevant cancer treatment."

According to the news reporters, the research concluded: "AmB-NC could be a potential delivery system for treatment of human cancer."

For more information on this research see: Research on the in vitro anticancer activity and in vivo tissue distribution of Amoitone B nanocrystals. Colloids and Surfaces B-Biointerfaces, 2014;117():258-266. Colloids and Surfaces B-Biointerfaces can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands (see also Oncology).

Our news correspondents report that additional information may be obtained by contacting L.L. Hao, Peking University, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100083, People's Republic of China. Additional authors for this research include J.J. Luan, D.R. Zhang, C.Y. Li, H.J. Guo, L.S. Qi, X.Q. Liu, T.T. Li and Q. Zhang.

Keywords for this news article include: Asia, Cancer, Beijing, Therapy, Oncology, People's Republic of China

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week